Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Wharton

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Obesity (Silver Spring, Md.)|January 19, 2023
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5Sean Wharton, Rachel L Batterham, Meena Bhatta, et al.
Obesity (Silver Spring, Md.)|September 7, 2025
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAINDeborah B Horn, Louis J Aronne, Sean Wharton, et al.
Diabetes, Obesity & Metabolism|June 21, 2023
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparisonCarel W le Roux, Emily R Hankosky, Duzhe Wang, et al.
The New England Journal of Medicine|October 30, 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisHenning Bliddal, Harold Bays, Sébastien Czernichow, et al.
Obesity (Silver Spring, Md.)|May 23, 2020
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Robert F Kushner, Salvatore Calanna, Melanie Davies, et al.
JAMA|December 11, 2023
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialLouis J Aronne, Naveed Sattar, Deborah B Horn, et al.
The New England Journal of Medicine|September 17, 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentSean Wharton, Louis J Aronne, Adam Stefanski, et al.
Obesity (Silver Spring, Md.)|November 4, 2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, et al.
The New England Journal of Medicine|November 13, 2024
Tirzepatide for Obesity Treatment and Diabetes PreventionAnia M Jastreboff, Carel W le Roux, Adam Stefanski, et al.
Lancet (London, England)|May 12, 2026
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trialDeborah B Horn, Louis J Aronne, Sean Wharton, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Obesity (Silver Spring, Md.)|January 19, 2023
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5Sean Wharton, Rachel L Batterham, Meena Bhatta, et al.
Obesity (Silver Spring, Md.)|September 7, 2025
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAINDeborah B Horn, Louis J Aronne, Sean Wharton, et al.
Diabetes, Obesity & Metabolism|June 21, 2023
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparisonCarel W le Roux, Emily R Hankosky, Duzhe Wang, et al.
The New England Journal of Medicine|October 30, 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisHenning Bliddal, Harold Bays, Sébastien Czernichow, et al.
Obesity (Silver Spring, Md.)|May 23, 2020
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Robert F Kushner, Salvatore Calanna, Melanie Davies, et al.
JAMA|December 11, 2023
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialLouis J Aronne, Naveed Sattar, Deborah B Horn, et al.
The New England Journal of Medicine|September 17, 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentSean Wharton, Louis J Aronne, Adam Stefanski, et al.
Obesity (Silver Spring, Md.)|November 4, 2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, et al.
The New England Journal of Medicine|November 13, 2024
Tirzepatide for Obesity Treatment and Diabetes PreventionAnia M Jastreboff, Carel W le Roux, Adam Stefanski, et al.
Lancet (London, England)|May 12, 2026
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trialDeborah B Horn, Louis J Aronne, Sean Wharton, et al.
Pageof 10